Agilent Technologies, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.3
Bullish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
A
Consensus analyst target of $160.69 is 40% above current price.
⚠ earnings contracting 4% year-over-year.
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $160.69 (+40.3%)
16 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
A
MRK
25.3×
Trailing P/E
31.5×
17.4×
Forward P/E
11.5×
18.3%
Profit Margin
13.6%
52.3%
Gross Margin
76.6%
19.9%
ROE
—
7.0%
Revenue Growth
4.9%
-3.6%
Earnings Growth
—
1.30
Beta
0.28
—
Price / Book
—
$32.4B
Market Cap
$277.0B
$104 – $160
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →